151 related articles for article (PubMed ID: 24789922)
1. Development of highly stable nifedipine solid-lipid nanoparticles.
Barman RK; Iwao Y; Funakoshi Y; Ranneh AH; Noguchi S; Wahed MI; Itai S
Chem Pharm Bull (Tokyo); 2014; 62(5):399-406. PubMed ID: 24789922
[TBL] [Abstract][Full Text] [Related]
2. Naringenin-loaded solid lipid nanoparticles: preparation, controlled delivery, cellular uptake, and pulmonary pharmacokinetics.
Ji P; Yu T; Liu Y; Jiang J; Xu J; Zhao Y; Hao Y; Qiu Y; Zhao W; Wu C
Drug Des Devel Ther; 2016; 10():911-25. PubMed ID: 27041995
[TBL] [Abstract][Full Text] [Related]
3. Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization.
Heiati H; Tawashi R; Phillips NC
J Microencapsul; 1998; 15(2):173-84. PubMed ID: 9532523
[TBL] [Abstract][Full Text] [Related]
4. Characterization and stability of nanostructured lipid carriers as drug delivery system.
Abbasalipourkabir R; Salehzadeh A; Abdullah R
Pak J Biol Sci; 2012 Feb; 15(3):141-6. PubMed ID: 22866544
[TBL] [Abstract][Full Text] [Related]
5. Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles.
Howard MD; Lu X; Jay M; Dziubla TD
Drug Dev Ind Pharm; 2012 Oct; 38(10):1270-9. PubMed ID: 22235767
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design.
Dudhipala N; Veerabrahma K
Drug Dev Ind Pharm; 2015; 41(12):1968-77. PubMed ID: 25830370
[TBL] [Abstract][Full Text] [Related]
7. Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells.
Vieira AC; Chaves LL; Pinheiro M; Ferreira D; Sarmento B; Reis S
Int J Nanomedicine; 2016; 11():2601-17. PubMed ID: 27354792
[TBL] [Abstract][Full Text] [Related]
8. Role of Isradipine Loaded Solid Lipid Nanoparticles on the Pharmacodynamic Effect in Rats.
Thirupathi G; Swetha E; Narendar D
Drug Res (Stuttg); 2017 Mar; 67(3):163-169. PubMed ID: 27992936
[TBL] [Abstract][Full Text] [Related]
9. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
Dudhipala N; Veerabrahma K
Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
[TBL] [Abstract][Full Text] [Related]
10. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles.
Vivek K; Reddy H; Murthy RS
AAPS PharmSciTech; 2007 Oct; 8(4):E83. PubMed ID: 18181544
[TBL] [Abstract][Full Text] [Related]
11. Freeze-dried nifedipine-lipid nanoparticles with long-term nano-dispersion stability after reconstitution.
Ohshima H; Miyagishima A; Kurita T; Makino Y; Iwao Y; Sonobe T; Itai S
Int J Pharm; 2009 Jul; 377(1-2):180-4. PubMed ID: 19446623
[TBL] [Abstract][Full Text] [Related]
12. Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line.
Bhatt H; Rompicharla SVK; Komanduri N; Aashma S; Paradkar S; Ghosh B; Biswas S
Curr Drug Deliv; 2018; 15(9):1271-1283. PubMed ID: 29732970
[TBL] [Abstract][Full Text] [Related]
13. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables.
Das S; Ng WK; Kanaujia P; Kim S; Tan RB
Colloids Surf B Biointerfaces; 2011 Nov; 88(1):483-9. PubMed ID: 21831615
[TBL] [Abstract][Full Text] [Related]
14. Development of Domperidone Solid Lipid Nanoparticles: In Vitro and In Vivo Characterization.
Shazly GA; Alshehri S; Ibrahim MA; Tawfeek HM; Razik JA; Hassan YA; Shakeel F
AAPS PharmSciTech; 2018 May; 19(4):1712-1719. PubMed ID: 29532427
[TBL] [Abstract][Full Text] [Related]
15. Topical Amphotericin B solid lipid nanoparticles: Design and development.
Butani D; Yewale C; Misra A
Colloids Surf B Biointerfaces; 2016 Mar; 139():17-24. PubMed ID: 26700229
[TBL] [Abstract][Full Text] [Related]
16. Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines.
Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Alsaidan YSM; Alfaiz SA; Haque A; Az A; Alhazzani K
Chem Phys Lipids; 2020 Nov; 233():105003. PubMed ID: 33096096
[TBL] [Abstract][Full Text] [Related]
17. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
18. Part I: Development and optimization of solid-lipid nanoparticles using Box-Behnken statistical design for ocular delivery of gatifloxacin.
Abul Kalam M; Sultana Y; Ali A; Aqil M; Mishra AK; Aljuffali IA; Alshamsan A
J Biomed Mater Res A; 2013 Jun; 101(6):1813-27. PubMed ID: 23255511
[TBL] [Abstract][Full Text] [Related]
19. Potential enhancement of metformin hydrochloride in solidified reverse micellar solution-based PEGylated lipid nanoparticles targeting therapeutic efficacy in diabetes treatment.
Kenechukwu FC; Nnamani DO; Duhu JC; Nmesirionye BU; Momoh MA; Akpa PA; Attama AA
Heliyon; 2022 Mar; 8(3):e09099. PubMed ID: 35309393
[TBL] [Abstract][Full Text] [Related]
20. Characterization of ergocalciferol loaded solid lipid nanoparticles.
Patel MR; San Martin-Gonzalez MF
J Food Sci; 2012 Jan; 77(1):N8-13. PubMed ID: 22260120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
